2,6-Dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol → HCID 66716728, compound
Reaction equation
Br[C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2[NH:17][C:18]1[CH:19]=[CH:20][C:21]([NH:24][CH:25]2[CH2:30][CH2:29][CH2:28][N:27](C(OC(C)(C)C)=O)[CH2:26]2)=[N:22][CH:23]=1.[Cl:38][C:39]1[CH:44]=[C:43](B2OC(C)(C)C(C)(C)O2)[CH:42]=[C:41]([Cl:54])[C:40]=1[OH:55]>>[CH:14]1([C:12]([C:6]2[CH:7]=[N:8][C:9]3[C:4]([C:5]=2[NH:17][C:18]2[CH:23]=[N:22][C:21]([NH:24][CH:25]4[CH2:30][CH2:29][CH2:28][NH:27][CH2:26]4)=[CH:20][CH:19]=2)=[CH:3][C:2]([C:43]2[CH:44]=[C:39]([Cl:38])[C:40]([OH:55])=[C:41]([Cl:54])[CH:42]=2)=[CH:11][CH:10]=3)=[O:13])[CH2:16][CH2:15]1Participants
Procedure
Following general procedure D, tert-butyl 3-(5-(6-bromo-3-(cyclopropanecarbonyl)quinolin-4-ylamino)pyridin-2-ylamino)piperidine-1-carboxylate (100 mg, 0.18 mmol) was reacted with 2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (78 mg, 0.27 mmol) to obtain the protected intermediate which was subjected to general procedure A-2 to afford the desired product (11 mg, 11% over 2 steps) as a yellow-brown solid: 1H NMR (500 MHz, CD3OD+TFA-d) δ 9.40 (s, 1H), 8.23 (dd, J=8.8, 1.9 Hz, 1H), 8.15 (s, 1H), 8.12 (d, J=2.6 Hz, 1H), 8.00 (d, J=8.7 Hz, 1H), 7.58 (dd, J=9.0, 2.7 Hz, 1H), 7.36 (s, 2H), 6.82 (d, J=9.2 Hz, 1H), 4.22 (ddd, J=14.0, 10.0, 3.8 Hz, 1H), 3.63 (dd, J=12.1, 3.5 Hz, 1H), 3.02 (td, J=11.9, 3.4 Hz, 1H), 2.89 (m, 2H), 2.12 (m, 1H), 1.86 (dtt, J=14.9, 11.2, 3.7 Hz, 1H), 1.71 (q, J=10.1 Hz, 1H), 1.21 (m, 4H); ESI MS m/z 548 [C29H27Cl2N5O2+H]+; HPLC 99.5% (AUC), tR=10.58 min.
Workup
- customto obtain the protected intermediate which
Sources & evidence
- ORD record
- ord-bd4c78b4f9464213babc1b6631ff43cf
- Source dataset
- uspto-grants-2015_09
- Patent number
- US09120749B2
Reaction notes
Loading…